Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

CRF: Circulating recombinant form; NNRTI: Non-nucleoside reverse-transcriptase inhibitor; NRTI: Nucleos(t)ide analog reverse-transcriptase inhibitor. Eight nucleos(t)ide analog reverse ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

Some of the same compounds used as RTIs can also block HBV replication; when used in this way they are referred to as polymerase inhibitors. [citation needed] While NRTIs and ... This, combined with ...

Generally, the dual NRTI backbone treatment of combination with a non-NRTI (NNRTI) or protease inhibitor (PI) should comprise a cytidine analogue (lamivudine, emtricitabine) and a thymidine ...

US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE: MRK) have announced new results from a Phase II clinical ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...

HIV-1 RT does not have proof-reading activity. This, combined with selective pressure from the drug, leads to mutations in reverse transcriptase that make the virus less susceptible to NRTIs and ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

The combination of these drugs with nucleoside reverse transcriptase inhibitors began the era of highly active antiretroviral therapy (HAART), transforming HIV infection from a death sentence to a ...